STOCK TITAN

[6-K] Galmed Pharmaceuticals Ltd. Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary

Galmed Pharmaceuticals reported that its Annual General Meeting of Shareholders was convened but adjourned for one day due to lack of quorum. The meeting will reconvene on October 29, 2025 at 4:00 p.m. Israel time at Meitar | Law Offices, 16 Abba Hillel Silver Rd., Ramat Gan.

This report is incorporated by reference into the company’s Registration Statements on Form S-8 (Nos. 333-206292, 333-227441, 333-284163, 333-290399) and Form F-3 (Nos. 333-272722, 333-283241).

Galmed Pharmaceuticals ha riferito che la sua Assemblea Generale degli Azionisti è stata convocata ma rinviata di un giorno per mancanza di quorum. L'assemblea si riconvoca per il 29 ottobre 2025 alle 16:00 ora di Israele presso Meitar | Law Offices, 16 Abba Hillel Silver Rd., Ramat Gan.

Questo rapporto è incorporato per riferimento nelle dichiarazioni di registrazione della società sui Moduli Form S-8 (No. 333-206292, 333-227441, 333-284163, 333-290399) e sul Modulo Form F-3 (No. 333-272722, 333-283241).

Galmed Pharmaceuticals informó que su Junta General de Accionistas fue convocada pero aplazada por un día debido a la falta de quórum. La reunión se reanuda el 29 de octubre de 2025 a las 4:00 p.m. hora de Israel en Meitar | Law Offices, 16 Abba Hillel Silver Rd., Ramat Gan.

Este informe está incorporado por referencia a las declaraciones de registro de la empresa en el Formulario S-8 (Nro. 333-206292, 333-227441, 333-284163, 333-290399) y en el Formulario F-3 (Nro. 333-272722, 333-283241).

갈메드 제약은 주주총회가 소집되었으나 정족수 부족으로 하루 연기되었다고 보고했습니다. 회의는 2025년 10월 29일 이스라엘 시간 오후 4시에 Meitar | 법률사무소, 16 Abba Hillel Silver Rd., Ramat Gan에서 재개될 예정입니다.

이 보고서는 회사의 Form S-8 (No. 333-206292, 333-227441, 333-284163, 333-290399) 및 Form F-3 (No. 333-272722, 333-283241) 등록서에 대한 참조로 포함되어 있습니다.

Galmed Pharmaceuticals a annoncé que son Assemblée générale annuelle des actionnaires a été convoquée mais ajournée d'un jour faute de quorum. La réunion se tiendra à nouveau le 29 octobre 2025 à 16h00, heure d'Israël chez Meitar | Law Offices, 16 Abba Hillel Silver Rd., Ramat Gan.

Ce rapport est incorporé par référence dans les déclarations d'enregistrement de la société sur le Formulaire S-8 (n° 333-206292, 333-227441, 333-284163, 333-290399) et sur le Formulaire F-3 (n° 333-272722, 333-283241).

Galmed Pharmaceuticals berichtete, dass seine Hauptversammlung zwar einberufen, aber aufgrund von quorum bis auf den nächsten Tag vertagt wurde. Die Versammlung wird am 29. Oktober 2025 um 16:00 israelischer Zeit bei Meitar | Law Offices, 16 Abba Hillel Silver Rd., Ramat Gan, wieder fortgesetzt.

Dieser Bericht ist durch Bezugnahme in die Registrierungsunterlagen des Unternehmens auf dem Formular S-8 (Nrn. 333-206292, 333-227441, 333-284163, 333-290399) und dem Formular F-3 (Nrn. 333-272722, 333-283241) aufgenommen.

جالمد للأدوية ذكرت أن اجتماع الجمعية العامة للمساهمين عُقد لكن تم تأجيله ليوم واحد بسبب نقص النصاب. ستعقد الجلسة مجددًا في 29 أكتوبر 2025 في 4:00 مساءً بتوقيت إسرائيل في Meitar | مكاتب المحاماة، 16 طريق أبي هليل سيلفر، رامات غان.

يتم دمج هذا التقرير كمرجع في بيانات تسجيل الشركة على النموذج S-8 (الأرقام 333-206292، 333-227441، 333-284163، 333-290399) وعلى النموذج F-3 (الأرقام 333-272722، 333-283241).

Positive
  • None.
Negative
  • None.

Galmed Pharmaceuticals ha riferito che la sua Assemblea Generale degli Azionisti è stata convocata ma rinviata di un giorno per mancanza di quorum. L'assemblea si riconvoca per il 29 ottobre 2025 alle 16:00 ora di Israele presso Meitar | Law Offices, 16 Abba Hillel Silver Rd., Ramat Gan.

Questo rapporto è incorporato per riferimento nelle dichiarazioni di registrazione della società sui Moduli Form S-8 (No. 333-206292, 333-227441, 333-284163, 333-290399) e sul Modulo Form F-3 (No. 333-272722, 333-283241).

Galmed Pharmaceuticals informó que su Junta General de Accionistas fue convocada pero aplazada por un día debido a la falta de quórum. La reunión se reanuda el 29 de octubre de 2025 a las 4:00 p.m. hora de Israel en Meitar | Law Offices, 16 Abba Hillel Silver Rd., Ramat Gan.

Este informe está incorporado por referencia a las declaraciones de registro de la empresa en el Formulario S-8 (Nro. 333-206292, 333-227441, 333-284163, 333-290399) y en el Formulario F-3 (Nro. 333-272722, 333-283241).

갈메드 제약은 주주총회가 소집되었으나 정족수 부족으로 하루 연기되었다고 보고했습니다. 회의는 2025년 10월 29일 이스라엘 시간 오후 4시에 Meitar | 법률사무소, 16 Abba Hillel Silver Rd., Ramat Gan에서 재개될 예정입니다.

이 보고서는 회사의 Form S-8 (No. 333-206292, 333-227441, 333-284163, 333-290399) 및 Form F-3 (No. 333-272722, 333-283241) 등록서에 대한 참조로 포함되어 있습니다.

Galmed Pharmaceuticals a annoncé que son Assemblée générale annuelle des actionnaires a été convoquée mais ajournée d'un jour faute de quorum. La réunion se tiendra à nouveau le 29 octobre 2025 à 16h00, heure d'Israël chez Meitar | Law Offices, 16 Abba Hillel Silver Rd., Ramat Gan.

Ce rapport est incorporé par référence dans les déclarations d'enregistrement de la société sur le Formulaire S-8 (n° 333-206292, 333-227441, 333-284163, 333-290399) et sur le Formulaire F-3 (n° 333-272722, 333-283241).

Galmed Pharmaceuticals berichtete, dass seine Hauptversammlung zwar einberufen, aber aufgrund von quorum bis auf den nächsten Tag vertagt wurde. Die Versammlung wird am 29. Oktober 2025 um 16:00 israelischer Zeit bei Meitar | Law Offices, 16 Abba Hillel Silver Rd., Ramat Gan, wieder fortgesetzt.

Dieser Bericht ist durch Bezugnahme in die Registrierungsunterlagen des Unternehmens auf dem Formular S-8 (Nrn. 333-206292, 333-227441, 333-284163, 333-290399) und dem Formular F-3 (Nrn. 333-272722, 333-283241) aufgenommen.

جالمد للأدوية ذكرت أن اجتماع الجمعية العامة للمساهمين عُقد لكن تم تأجيله ليوم واحد بسبب نقص النصاب. ستعقد الجلسة مجددًا في 29 أكتوبر 2025 في 4:00 مساءً بتوقيت إسرائيل في Meitar | مكاتب المحاماة، 16 طريق أبي هليل سيلفر، رامات غان.

يتم دمج هذا التقرير كمرجع في بيانات تسجيل الشركة على النموذج S-8 (الأرقام 333-206292، 333-227441، 333-284163، 333-290399) وعلى النموذج F-3 (الأرقام 333-272722، 333-283241).

Galmed Pharmaceuticals 报告称其股东年度大会已召集但因缺乏法定人数被推迟一天。会议将于2025年10月29日以色列时间下午4点在 Meitar | Law Offices,Ramat Gan 的 16 Abba Hillel Silver Rd 召开重新集合。

本报告被作为参考并并入公司在Form S-8(编号 333-206292、333-227441、333-284163、333-290399)及Form F-3(编号 333-272722、333-283241)的注册声明中。

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

 

For the Month of October 2025

 

001-36345

(Commission File Number)

 

GALMED PHARMACEUTICALS LTD.

(Exact name of Registrant as specified in its charter)

 

c/o Meitar Law Offices Abba Hillel Silver Rd.,

Ramat Gan, 5250608

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

 

 

 

 

 

 

On October 28, 2025, Galmed Pharmaceuticals Ltd. (the “Company”) convened an Annual General Meeting of Shareholders (the “Meeting”), however, the Meeting was adjourned for one day to the same time and place due to lack of quorum. Accordingly, the Meeting will be reconvened on Wednesday, October 29, 2025 at 4:00 p.m., Israel time at the at the offices of Meitar | Law Offices, legal counsel to the Company at 16 Abba Hillel Silver Rd., Ramat Gan, 5250608, Israel.

 

This Form 6-K is incorporated by reference into the Company’s Registration Statements on Form S-8 (Registration Nos. 333-206292, 333-227441, 333-284163, and 333-290399) and the Company’s Registration Statement on Form F-3 (Registration Nos. 333-272722 and 333-283241).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Galmed Pharmaceuticals Ltd.
     
Date: October 28, 2025 By: /s/ Allen Baharaff
  Allen Baharaff
  President and Chief Executive Officer

 

 

 

FAQ

What did Galmed (GLMD) announce in this Form 6-K?

The company adjourned its Annual General Meeting due to lack of quorum and will reconvene on October 29, 2025 at 4:00 p.m. Israel time in Ramat Gan.

Why was Galmed's AGM adjourned?

It was adjourned for one day due to a lack of quorum.

When and where will the Galmed AGM reconvene?

On October 29, 2025 at 4:00 p.m. Israel time at Meitar | Law Offices, 16 Abba Hillel Silver Rd., Ramat Gan.

Which registration statements does this 6-K incorporate by reference?

It is incorporated into Form S-8 Nos. 333-206292, 333-227441, 333-284163, 333-290399 and Form F-3 Nos. 333-272722, 333-283241.

Who signed the report for Galmed Pharmaceuticals?

It was signed by Allen Baharaff, President and Chief Executive Officer.

What is the form type of this filing?

This is a Form 6-K report of a foreign private issuer.
Galmed Pharmaceu

NASDAQ:GLMD

GLMD Rankings

GLMD Latest News

GLMD Latest SEC Filings

GLMD Stock Data

7.56M
5.41M
1.19%
1.42%
2.95%
Biotechnology
Healthcare
Link
Israel
Ramat Gan